News Releases

Below are the latest News Releases for Clearmind Medicine Inc.

25

April

2025

Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
Read More
23

April

2025

Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites
Read More
21

April

2025

Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts
Read More
17

April

2025

Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior
Read More
10

April

2025

Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder
Read More
8

April

2025

Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds
Read More
1

April

2025

Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment
Read More
21

March

2025

Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S.
Read More
19

March

2025

Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination
Read More
18

March

2025

Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients
Read More
10

March

2025

Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea
Read More
4

February

2025

Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico
Read More
6

January

2025

Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
Read More
2

January

2025

Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office
Read More
24

December

2024

Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial
Read More